AI-ACCELERATED DRUG DISCOVERY

The future of drug design

RECEPTOR.AI provides an end-to-end small molecule drug discovery platform for precision and personalised medicine to achieve ultimate selectivity between highly similar off-target proteins.

Our mission
RECEPTOR.AI's mission is to create superior drugs, which are safe, efficient and successful in clinical trials by developing a next generation drug discovery platform based on the synergy of AI, computational chemistry and biology.

We aim to improve access to AI drug discovery via our AI platform which is integrated with wet labs to make the drug discovery process more efficient.
Our vision
We dream about a world where new drugs are developed so fast, that new diseases have no chances to spread.

We envision radical minimization of drug testing on animals and humans with improvement of their safety and efficiency by combining advanced AI with novel biomimetic technologies.
Our team
The Receptor.AI team comprises over 20 experts in the fields of AI, computational chemistry, and biology, bringing together a diverse range of scientific backgrounds and a wealth of industry experience.

Dr. Alan Nafiev

Chief Executive Officer,
Co-founder

Ph.D. holder in Data Science with expertise
in leading AI-driven drug discovery projects. He specializes in designing cloud systems for life sciences, particularly focusing on AI-powered workflows. With a strong background in B2B start-ups, he brings valuable experience to the intersection of data science and the life sciences industry.

Dr. Sergii Starosyla

Chief Technical Officer,
Co-founder

PhD in Molecular Biology with 13 years of experience in drug discovery and scientific software development. Medicinal chemist, expert in development of machine-learning models, algorithms for pharmacophore modelling and molecular docking. Author of number of patented anticancer and anti-microbic biologically active compounds.

Dr. Semen Yesylevskyy

Chief Scientific Officer,

Co-founder

PhD, Dr.Sci. in biophysics. 20 years of experience in molecular modelling, computational drug discovery and scientific software development. Author of unique techniques and algorithms in simulations of curved and asymmetric lipid membranes and assessment of drug-membrane interactions.

Prof. Mikhail Bogdanov

Scientific Advisor

PhD, Professor of Biochemistry and Molecular Biology at University of Texas Medical School with 30+ years of experience in experimental studies of lipid membranes and membrane proteins. An expert in design and assessment of membrane targeting compounds.

Prof. Kevin Burgess

Scientific Advisor

Renowned Rachal Professor of Chemistry at Texas A&M, who has made significant contributions to the fields of medicinal and combinatorial chemistry. He applies his expertise in peptido-mimetics, hybrid-peptides and PPI targeting.

Prof. Christophe Ramseyer

Scientific Advisor

PhD, Professor of Physics with 20+ years of experience  in quantum chemistry and computational drug design. An expert in simulating interactions of theragnostic nanoparticles with the cell membrane.

Roman Stratiichuk

AI Drug Discovery
Project Manager

Leonid Popryho

Lead AI Engineer

Taras Voitsitskyi

AI Engineer
Computational Chemistry

Ihor Koleiev

Scientist
Medicinal Chemist

Roman Zhytar

AI Platform Developer

Zakhar Ostrovsky

AI Solutions Developer
for Drug Discovery

Volodymyr Vozniak

AI Solutions Developer
for Drug Discovery

Pavlo Henitsoi

Drug Discovery
Platform Developer

Ivan Khorpachov

AI Drug Discovery
Cloud Engineer

Yana Shevchenko

Quality Assurance Engineer

Vladyslav Husak

TechBio Prospecting
Specialist

Myroslav Uiazdovskyi

BD Executive, 

AI-Enabled Therapeutics

Tetiana Skakun

Marketing Operations
Specialist

Anastasiia Vituk

TechBio Sales
Associate

Book a demo
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.